Not Yet RecruitingPhase 1

A Single Ascending Dose of HRS-4029 in Healthy Subjects

China55 participantsStarted 2025-04

Plain-language summary

The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age between 18 to 55 years.
✓. Body mass index (BMI) of 19.0 to 28.0 kg/m2 (inclusive).
✓. Agreed to take effective contraceptive measures during and 3 months after the last dose of the study period.
✓. Understand in detail the content, procedure and possible adverse effects of the trial, and voluntarily sign the written informed consent form (ICF).

Exclusion criteria

✕. Diseases with abnormal clinical manifestations that occurred before screening or are currently occurring and need to be excluded.
✕. Vital signs, physical examination, 12-lead electrocardiogram,or laboratory examination deemed clinically significant by the investigator .
✕. Subjects with positive tests for infectious diseases.
✕. Female who are pregnant or breastfeeding.
✕. Unable to tolerate venipunctures or have a history of fainting needles and blood.
✕. Historic abuse of alcoholic beverages
✕. Smoke ≥5 cigarettes per day within 3 months prior to the study
✕. History of drug abuse.

What they're measuring

The incidence and severity of adverse events

Timeframe: From ICF signing date to Day15

Trial details

NCT IDNCT06905314

SponsorBeijing Suncadia Pharmaceuticals Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-10

Contact for this trial

Yuanyuan Huang

0518-82342973 yuanyuan.huang@hengrui.com

View on ClinicalTrials.gov More Acute Ischemic Stroke trials